Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P LeBrun

Showing results (231-240 of 409) with videos related to

Pageof 41
Sort By:
Diabetologia|May 26, 2010
The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretionP Lebrun, E Cognard, P Gontard, et al.
Diabetologia|August 13, 2009
Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in miceP Lebrun, E Cognard, R Bellon-Paul, et al.
Gynecologic Oncology|January 18, 2016
First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16J I Weberpals, M S Amin, B E Chen, et al.
Annales D'Endocrinologie|April 6, 1999
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]F Eisinger, N Alby, A Bremond, et al.
Annales De Genetique|April 24, 1999
[INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer]F Eisinger, N Alby, A Bremond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc CommitteeF Eisinger, N Alby, A Bremond, et al.
Bulletin Du Cancer|April 22, 1999
[Inserm ad hoc committee: Recommendations for the management of women with a genetic risk for developing cancer of the breast and/or the ovary]F Eisinger, N Alby, A Bremond, et al.
Leukemia & Lymphoma|January 17, 2020
Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and <i>BCL2</i> gene alterationsLina Chen, Kathrin Tyryshkin, Alison Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphomaRashmi S Goswami, Eshetu G Atenafu, Yali Xuan, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|February 21, 2018
AEgIS at ELENA: outlook for physics with a pulsed cold antihydrogen beamM Doser, S Aghion, C Amsler, et al.
Pageof 41

Showing results (231-240 of 409) with videos related to

Sort By:
Pageof 41
Diabetologia|May 26, 2010
The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretionP Lebrun, E Cognard, P Gontard, et al.
Diabetologia|August 13, 2009
Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in miceP Lebrun, E Cognard, R Bellon-Paul, et al.
Gynecologic Oncology|January 18, 2016
First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16J I Weberpals, M S Amin, B E Chen, et al.
Annales D'Endocrinologie|April 6, 1999
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]F Eisinger, N Alby, A Bremond, et al.
Annales De Genetique|April 24, 1999
[INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer]F Eisinger, N Alby, A Bremond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc CommitteeF Eisinger, N Alby, A Bremond, et al.
Bulletin Du Cancer|April 22, 1999
[Inserm ad hoc committee: Recommendations for the management of women with a genetic risk for developing cancer of the breast and/or the ovary]F Eisinger, N Alby, A Bremond, et al.
Leukemia & Lymphoma|January 17, 2020
Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and <i>BCL2</i> gene alterationsLina Chen, Kathrin Tyryshkin, Alison Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphomaRashmi S Goswami, Eshetu G Atenafu, Yali Xuan, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|February 21, 2018
AEgIS at ELENA: outlook for physics with a pulsed cold antihydrogen beamM Doser, S Aghion, C Amsler, et al.
Pageof 41